文献速递颈动脉与弓上血管

经颈动脉血运重建术在各类主动脉弓类型及动脉粥样硬化程度下均优于经股动脉颈动脉支架置入术

Transcarotid artery revascularization outperforms transfemoral carotid artery stenting regardless of aortic arch type or degree of atherosclerosis.
PubMed 文献 · J Vasc Surg · 2024-08-10

基于血管质量倡议数据库2016年9月至2023年10月共20,114例颈动脉支架置入患者,按主动脉弓类型和粥样硬化程度分四组比较经颈动脉血运重建术(TCAR)与经股动脉颈动脉支架置入术(TFCAS)。在轻度粥样硬化合并简单弓(A组)、轻度粥样硬化合并复杂弓(B组)及重度粥样硬化合并简单弓(C组)中,TCAR的院内卒中/死亡风险及1年死亡风险均低于TFCAS;在重度粥样硬化合并复杂弓(D组)中无显著差异。

要点

  • A组TCAR较TFCAS的卒中/死亡风险降低(OR 0.43,95%CI 0.31-0.61,P < .001),1年死亡风险亦降低(HR 0.42,95%CI 0.32-0.57,P < .001)。
  • B组TCAR较TFCAS的卒中/死亡风险降低70%(OR 0.30,95%CI 0.12-0.75,P = .01)。
  • D组(重度粥样硬化合并复杂弓)TCAR与TFCAS的卒中/死亡风险无显著差异(OR 0.91,95%CI 0.39-2.16,P = .834)。

核心结论

  • 在简单及复杂主动脉弓解剖患者中,TCAR较TFCAS更安全;作者认为这可能与血流逆转相较于远端栓塞保护的效率有关。
  • 作者指出,若未实施多学科协作和恰当的患者选择,美国医疗保险和医疗补助服务中心当前的决定可能在全国范围内增加颈动脉支架置入术的卒中和死亡结局。

研究设计与样本

  • 回顾性队列研究,数据来源于血管质量倡议数据库,纳入2016年9月至2023年10月期间所有接受颈动脉支架置入术的患者。
  • 共纳入20,114例患者,按主动脉弓类型和粥样硬化程度分为四组:A组(轻度粥样硬化且I/II型弓)12,980例(64.53%)、B组(轻度粥样硬化且III型弓)1,175例(5.84%)、C组(中/重度粥样硬化且I/II型弓)5,124例(25.47%)、D组(中/重度粥样硬化且III型弓)835例(4.15%)。
  • 主要结局为院内复合卒中或死亡;采用方差分析和χ2检验比较基线特征,逻辑回归模型校正潜在混杂因素并进行 backward stepwise selection,Kaplan-Meier生存估计、log rank检验和多变量Cox回归模型分析1年死亡风险比。

主要发现

  • TCAR在四组中的实施比例分别为72.21%、67.06%、74.94%和69.22%(P < .001)。
  • 与轻度弓粥样硬化患者相比,C组和D组中重度弓粥样硬化患者更可能为女性、高血压、吸烟者并患有慢性肾脏病;B组和D组中III型弓患者更可能在术前表现为卒中。
  • 多变量分析显示,在A组中TCAR较TFCAS的卒中/死亡风险降低(OR 0.43,95%CI 0.31-0.61,P < .001),1年死亡风险亦降低(HR 0.42,95%CI 0.32-0.57,P < .001)。
  • B组中TCAR较TFCAS的卒中/死亡风险降低70%(OR 0.30,95%CI 0.12-0.75,P = .01)。
  • C组中TCAR较TFCAS的卒中/死亡风险降低(OR 0.66,95%CI 0.44-0.97,P = .037);D组中TCAR与TFCAS的卒中/死亡风险无显著差异(OR 0.91,95%CI 0.39-2.16,P = .834)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Centers for Medicare and Medicaid Services now approve reimbursement for transfemoral carotid artery stenting (TFCAS) in the treatment of standard-risk patients with carotid artery occlusive disease. TFCAS in patients with complex aortic arch anatomy is known to be challenging with worse outcomes. Transcarotid artery revascularization (TCAR) could be a preferable alternative in these patients owing to avoiding the aortic arch and using flow reversal during stent deployment. We aim to compare the outcomes of TCAR vs TFCAS across all aortic arch types and degrees of arch atherosclerosis. METHODS: All patients undergoing carotid artery stenting between September 2016 and October 2023 were identified in the Vascular Quality Initiative database. Patients were stratified into four groups: Group A (mild atherosclerosis and type I/II arch), Group B (mild atherosclerosis and type III arch), Group C (moderate/severe atherosclerosis and type I/II arch), and Group D (moderate/severe atherosclerosis and type III arch). The primary outcome was in-hospital composite stroke or death. Analysis of variance and χ2 tests analyzed differences for baseline characteristics. Logistic regression models were adjusted for potential confounders, and backward stepwise selection was implemented to identify significant variables for inclusion in the final models. Kaplan-Meier survival estimates, log rank test, and multivariable Cox regression models analyzed hazard ratios for 1-year mortality. RESULTS: A total of 20,114 patients were included (Group A: 12,980 [64.53%]; Group B: 1175 [5.84%]; Group C: 5124 [25.47%]; and Group D: 835 [4.15%]). TCAR was more commonly performed across the four groups (72.21%, 67.06%, 74.94%, and 69.22%; P < .001). Compared with patients with mild arch atherosclerosis, patients with advanced arch atherosclerosis in Group C and Group D were more likely to be female, hypertensive, smokers, and have chronic kidney disease. Patients with type III arch in Group B and Group D were more likely to present with stroke preoperatively. On multivariable analysis, TCAR had less than one-half the risk of stroke/death and 1-year mortality compared with TFCAS in the patients with the mildest atherosclerosis and simple arch anatomy (Group A) (odds ratio [OR], 0.43; 95% confidence interval [CI], 0.31-0.61; P < .001; hazard ratio, 0.42; 95% CI, 0.32-0.57; P < .001). Group B patients with similar atherosclerosis but more complex arch anatomy had 70% lower odds of stroke/death with TCAR compared with TFCAS (OR, 0.30; 95% CI, 0.12-0.75; P = .01). Similar findings were also evident in patients with more severe atherosclerosis and simple arch anatomy (OR, 0.66; 95% CI, 0.44-0.97; P = .037). There was no significant difference in odds of stroke/death in patients with advanced arch atherosclerosis and complex arch (Group D) (OR, 0.91; 95% CI, 0.39-2.16; P = .834). CONCLUSIONS: TCAR is safer than TFCAS in patients with simple and advanced arch anatomy. This could be related to the efficiency of flow reversal vs distal embolic protection. The current Centers for Medicare and Medicaid Services decision will likely increase stroke and death outcomes of carotid stenting nationally if multidisciplinary approach and appropriate patient selection are not implemented.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hamouda M, Alqrain S, Zarrintan S, et al. Transcarotid artery revascularization outperforms transfemoral carotid artery stenting regardless of aortic arch type or degree of atherosclerosis. J Vasc Surg. 2024. PMID: 39134214. doi:10.1016/j.jvs.2024.07.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。